Accrued liabilities consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
(in thousands) |
|
2024 |
|
|
2023 |
|
Accrued compensation |
|
$ |
13,305 |
|
|
$ |
5,918 |
|
Cystic Fibrosis Foundation liability |
|
|
7,443 |
|
|
|
7,633 |
|
Income tax payable |
|
|
— |
|
|
|
641 |
|
Current portion of operating lease liability |
|
|
3,552 |
|
|
|
4,309 |
|
Clinical trial accruals |
|
|
2,828 |
|
|
|
2,333 |
|
Vinbiocare contractual liabilities |
|
|
2,421 |
|
|
|
2,514 |
|
Legal accrual |
|
|
130 |
|
|
|
177 |
|
Other accrued research and development expenses |
|
|
9,102 |
|
|
|
8,356 |
|
Total |
|
$ |
38,781 |
|
|
$ |
31,881 |
|
|